## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Hassan Fred</u>						2. Issuer Name and Ticker or Trading Symbol  EyePoint Pharmaceuticals, Inc. [ EYPT ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owne				
(Last) (First) (Middle) C/O EYEPOINT PHARMACEUTICALS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 01/03/2025									Officer below)	(give title		Other (s below)	specify
480 PLEASANT STREET					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) WATER	,		02472												Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(5	State)	(Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transa Date (Month/D.				Date	Execu ay/Year) if any		A. Deemed secution Date, any lonth/Day/Year)		3. Transaction Code (Instr. 8)  4. Securi Dispose 55		ties Acquired (A) o d Of (D) (Instr. 3, 4 a		r and	5. Amour Securitie Beneficia Owned F Reported	es For ally (D) Following (I)		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code	v	Amount	(A) or (D)	Pric	e e	Transact (Instr. 3 a	ion(s)			(111341. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye	Cod	nsactior de (Instr.			6. Date Exercisable a Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		Derivat Securit		9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e O s Fe illy D	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Cod	de V	(A)	(D)	Date Exercisable		xpiration ate	Title	Amou or Numb of Share	er					
Stock Option (Right to Buy)	\$8.26	01/03/2025		А		40,000		01/03/2026	0	1/03/2035	Common Stock	40,00	00	\$0.00	40,000	)	D	

Explanation of Responses:

Remarks:

/s/ Ron Honig, Attorney-in-Fact 01/07/2025

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $<sup>^{\</sup>star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).